•GLP-1(28-36)amide
HY-P3101

CAS No.:1225021-13-5

Molecular Formula:

C54H85N15O9

Molecular Weight:

1088.35

Sequence:

Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2

Screening Libraries

Cat. No.:•Sequence Shortening: FIAWLVKGR-NH2
GCGR

Pathway:

GPCR/G Protein

Storage:

Sealed storage, away from moisture and light-80°C

2 years-20°C

1 yearProteins

Target:PowderInhibitors

Product Data Sheet* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moistureand light)

SOLVENT & SOLUBILITY
In VitroDMSO : 33.33 mg/mL (30.62 mM; Need ultrasonic)

Solvent

Mass1 mg5 mg

10 mg

1 mM

0.9188 mL

4.5941 mL

9.1882 mL

5 mM

0.1838 mL

0.9188 mL

1.8376 mL

10 mM

0.0919 mL

0.4594 mL

0.9188 mL

Concentration
Preparing
Stock Solutions

Please refer to the solubility information to select the appropriate solvent.
In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (2.30 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (2.30 mM); Clear solution

BIOLOGICAL ACTIVITY
Description

GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral
endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial
permeability transition (MPT). GLP-1(28-36)amide has anti-diabetic and cardioprotection effects[1].

In Vitro

Different from DPP-IV, NEP, which cleaves GLP-1(7-36)amide or GLP-1(9-36)amide to generate GLP-1(28-36)amide, is widelydistributed in endothelial cells, vascular smooth muscle cells, cardiac cells and renal epithelial cells[1].

Page 1 of 2

www.MedChemExpress.com

GLP-1(28-36)amide (100 nM) treatment on hepatocytes for 24 hours directly modulates mitochondrial oxidative metabolism,
such as gluconeogenesis in mitochondria of hepatocytes[1].
The plasma half-life of GLP-1(28-36)amide is longer in human hepatocytes (t1/2 = 24 min) than that in mouse hepatocytes (t[1]1/2 = 13 min) .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo

The administration of GLP-1(28-36)amide at a rate of 18.5 nmol/kg BW/day for 9 weeks to diet-induced obese micediminishes the development of hepatic steatosis[1].
The intraperitoneal injection of 18 nmol/kg GLP-1(28-36)amide once daily for 9 weeks show cytoprotective effect onpancreatic β cells by increasing mass and promoting proliferation in a β-cell injury diabetic mouse model[1].
An in vivo study in high-fat diet-fed mice indicates that a six-week administration of 18.5 nmol/kg GLP-1(28-36)amide
improved hepatic glucose disposal, which is associated with increased cAMP levels and phosphorylation of PKA target[1].
Administered GLP-1(28-36)amide for 20 min to male C57BL6/J mice (10-12 week old), then isolated hearts underwent 30 minof global ischemia and 40 min of reperfusion, the recovery of left ventricular developed pressure (LVDP) is significantly
greater in GLP-1(28-36)amide group compared to vehicle-treated hearts[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES[1]. Bilan Zhou, et al. GLP-1(28-36)amide, a Long Ignored Peptide Revisited. Open Biochem J. 2014 Dec 31;8:107-11.

McePdfHeight

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2

www.MedChemExpress.com